Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6301641 | 0.94 | PDE2A (0.51) | PDE2APPARGRAB9ACYP1A2SIRT2 | |
| SCHEMBL6487796 | 0.93 | PPARG (0.52) | PDE2APPARGSIRT2SIRT1 | |
| SCHEMBL6488294 | 0.90 | PPARG (0.42) | PDE2APPARGRAB9ASIRT2SIRT1 | |
| SCHEMBL6497415 | 0.89 | PPARG (0.52) | PPARGRAB9AALOX5APNPC1 | |
| SCHEMBL6490261 | 0.88 | CYP1A2 (0.42) | PDE2ARAB9ACYP1A2SIRT2SIRT1 | |
| SCHEMBL6492014 | 0.87 | SIRT2 (0.42) | PDE2APPARGALOX15SIRT2SIRT1 | |
| SCHEMBL6487661 | 0.87 | PDE2A (0.43) | PDE2APPARGALOX15SIRT2SIRT1 | |
| SCHEMBL6489299 | 0.84 | PPARG (0.45) | PPARGALOX5AP | |
| SCHEMBL6307363 | 0.83 | PPARG (0.51) | PPARGALOX5AP | |
| SCHEMBL6168954 | 0.83 | HDAC1 (0.54) | PDE2AALOX15RAB9ACYP1A2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PDE2A 1017/4885PPARG 233/4885ALOX15 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.